Summit Therapeutics plc Summit Therapeutics Plc : Change Of Registered Office

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit', 'the Company') 
 
   SUMMIT ANNOUNCES CHANGE OF REGISTERED COMPANY ADDRESS 
 
   Oxford, UK, 30 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: 
SMMT), the drug discovery and development company advancing therapies 
for Duchenne muscular dystrophy and Clostridium difficile infection, 
announces that the registered office address of the Company has changed 
to 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, UK 
with immediate effect. 
 
   All other details remain the same including the Company's website 
(www.summitplc.com), telephone number ([phone]) and fax 
number ([phone]). 
 
   This announcement has been made in accordance with Rule 17 of the AIM 
Rules for Companies. 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease Duchenne 
muscular dystrophy and the infectious disease C. difficile infection. 
Further information is available at www.summitplc.com and Summit can be 
followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
Summit 
 Glyn Edwards / Richard Pye (UK office)         Tel: [phone] 
 Erik Ostrowski / Michelle Avery (US office)    [phone] 
Cairn Financial Advisers LLP 
 (Nominated Adviser)                            Tel: [phone] 
 Liam Murray / Tony Rawlinson 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

March 30, 2017 09:00 ET (13:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.